Morgan Stanley
PRCT icon

Morgan Stanley’s Procept Biorobotics PRCT Stock Holding History

Morgan Stanley’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Sell
605,407
-372,000
-38% -$9.31M ﹤0.01% 3443
2026
Q1 		$24.4M Buy
977,407
+133,916
+16% +$3.77M ﹤0.01% 2768
2025
Q4 		$26.5M Sell
843,491
-183
-0% -$6.07K ﹤0.01% 2667
2025
Q3 		$30.1M Buy
843,674
+267,302
+46% +$12.2M ﹤0.01% 2481
2025
Q2 		$33.2M Buy
576,372
+54,018
+10% +$3.05M ﹤0.01% 2300
2025
Q1 		$30.4M Sell
522,354
-235,046
-31% -$16M ﹤0.01% 2277
2024
Q4 		$61M Buy
757,400
+106,627
+16% +$9.11M ﹤0.01% 1657
2024
Q3 		$52.1M Buy
650,773
+82,268
+14% +$5.84M ﹤0.01% 1789
2024
Q2 		$34.7M Buy
568,505
+262,338
+86% +$15.6M ﹤0.01% 2102
2024
Q1 		$15.1M Buy
306,167
+96,744
+46% +$4.6M ﹤0.01% 2980
2023
Q4 		$8.78M Buy
209,423
+120,634
+136% +$4.11M ﹤0.01% 3460
2023
Q3 		$2.91M Sell
88,789
-34,981
-28% -$1.19M ﹤0.01% 4122
2023
Q2 		$4.38M Sell
123,770
-14,559
-11% -$481K ﹤0.01% 3876
2023
Q1 		$3.93M Sell
138,329
-6,568
-5% -$232K ﹤0.01% 3969
2022
Q4 		$6.02M Buy
144,897
+61,610
+74% +$2.65M ﹤0.01% 3587
2022
Q3 		$3.45M Buy
83,287
+26,461
+47% +$1.06M ﹤0.01% 3987
2022
Q2 		$1.86M Sell
56,826
-6,753
-11% -$246K ﹤0.01% 4591
2022
Q1 		$2.22M Buy
63,579
+24,706
+64% +$595K ﹤0.01% 4436
2021
Q4 		$973K Buy
38,873
+38,673
+19,337% +$1.43M ﹤0.01% 5088
2021
Q3 		$8K Buy
+200
New +$7.68K ﹤0.01% 7397

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley's PRCT Position: Q2 2026 in Review

Morgan Stanley reduced its Procept Biorobotics (PRCT) stake by 38% in Q2 2026, selling an estimated $9.31M and leaving 605,407 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3443.

Morgan Stanley first reported a position in PRCT in Q3 2021 and has held it in 20 quarters since. The position peaked at $61M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Morgan Stanley held 605,407 shares of Procept Biorobotics worth $13.7M as of Q2 2026.
  • Morgan Stanley sold 372,000 Procept Biorobotics shares in Q2 2026, an estimated $9.31M.
  • Procept Biorobotics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3443 holding.
  • Morgan Stanley first reported a position in Procept Biorobotics in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Procept Biorobotics position peaked at $61M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.